ES-481 May Reduce Seizures In Hard-To-Control Epilepsy

What was studied

This study tested ES-481, a new add-on anti-seizure medicine, in adults with drug-resistant epilepsy. These were people who still had seizures despite taking available anti-seizure medicines. The trial took place at four epilepsy centers in Australia.

It was a Phase 2A study. Twenty-two adults were randomly assigned to receive different doses of ES-481 and placebo at different times in a double-blind, randomized, dose-titration, cross-over, placebo-controlled design. Seventeen finished the double-blind phase, and 16 continued into an open-label extension where ES-481 was studied for up to 36 weeks.

What they found

Overall, seizure diaries suggested greater improvement in seizure frequency during ES-481 treatment than during placebo, but the overall comparison did not reach conventional statistical significance (p = 0.097). At the highest tested dose, 75 mg twice daily, seizure frequency improved by 80% on ES-481 compared with 49% on placebo for the corresponding week, and this difference was statistically significant (p = 0.047). Lower doses did not show a significant difference from placebo.

The study did not find a significant difference between ES-481 and placebo in EEG epileptiform or seizure discharges lasting more than 3 seconds. Serious treatment-emergent adverse events were not significantly different between ES-481 and placebo. Adverse events of special interest such as dizziness and drowsiness were reported more often with ES-481, but this difference was not statistically significant (p = 0.052). In the open-label extension, treatment was reported to be well tolerated for up to 36 weeks.

Limits of the evidence

This was a small, early-stage study with only 22 participants, and only 17 completed the blinded treatment phase. Because of the small sample, the results are uncertain and may differ in larger studies.

The trial suggests possible benefit, but it does not establish how well ES-481 will work in the wider epilepsy population. The clearest signal was seen at the highest dose, and the overall seizure result was not statistically significant. The study included adults only, so it does not show whether the medicine is safe or effective for children. The open-label extension also has limits because it was not blinded.

For families and caregivers

For families, this study offers an early sign that ES-481 might become another option for adults with hard-to-control epilepsy. The highest dose showed potential benefit, and the medicine was generally described as safe and well tolerated in this small trial.

But this is not enough to know yet how well ES-481 works, who it helps most, or how it compares with current treatments. Larger studies are needed before firm conclusions can be made.

What to watch next

Stronger evidence would come from larger trials that include more adults, study the most promising dose more closely, and confirm seizure effects and side effects over longer follow-up.

Terms in this summary

drug-resistant epilepsy

Epilepsy that continues to cause seizures even after trying anti-seizure medicines.

add-on anti-seizure medication

A seizure medicine used together with a person's current epilepsy medicines, not by itself.

Phase 2A trial

An early study in people that looks at safety and gives a first idea of whether a treatment might work.

double-blind

Neither the participants nor the researchers know who is getting the study drug or placebo during that part of the trial.

placebo

A look-alike treatment with no active drug, used for comparison.

cross-over trial

A study where participants receive more than one treatment at different times.

pharmacokinetics

How the body absorbs, breaks down, and clears a medicine.

EEG

A test that records the brain's electrical activity.